Kaitlyn Bader, Senior Editor

Brauer’s textbook can be purchased through Amazon and Barnes & Noble.

Check in throughout the month to learn more about the latest treatment pearls and research findings in DermIQ’s spotlight on atopic dermatitis.

No concerns were cited about the clinical data package, safety, or label of lebrikizumab.

Prepare your patients with helpful resources each week throughout National Eczema Awareness Month.

Learn more about the in-depth topics covered in the September 2023 Frontline Forum BCC management supplement of Dermatology Times.

Late-breaking data, oral presentations, and ePosters from Incyte’s dermatology portfolio will be presented in Berlin, Germany, October 11-14.

NPs and PAs in dermatology are encouraged to monitor their own cardiovascular health and support their peers.

Learn more about the in-depth topics covered in the September 2023 print issue of Dermatology Times.

The survey conducted by Almirall included participants in the US and Europe.

This week’s collection of the latest dermatologic studies covers chronic pruritus of unknown origin, vaccinating dermatology providers for HPV, body dysmorphic disorder among Lebanese women, and a case report of a pleomorphic dermal sarcoma with metastasis to the lung.

ICYMI, this week we had articles about periorbital rejuvenation, treating all skin tones, improving basal cell carcinoma management, and more.

Eligible candidates should apply by October 15, 2023, and one candidate will match in March 2024.

Yale School of Medicine researchers found tetracycline-class antibiotics were the most prescribed acne treatment for adult female patients between 2002 and 2016.

FDA action is no longer expected in Q3 of 2023.

This week’s collection of the latest dermatologic studies covers dermatologic care for patients with disorders of sex development, stem cell transplantation for vitiligo, switching biologic therapies for psoriasis, and combination therapy for hidradenitis suppurativa.

ICYMI, this week we had articles about deucravacitinib's year in review, patient satisfaction in cosmetic procedures, confronting racial disparities in dermatology, and more.

Martin presented clinical pearls regarding business management and facial balancing in Dallas, Texas.

This week’s collection of the latest dermatologic studies covers aseptic facial granulomas, chronic spontaneous urticaria and IgE, a case review of crusted scabies, and the safety and tolerability of onabotulinumtoxinA.

To further discuss the changing landscape of skin of color representation in dermatology, Christopher Bunick, MD, PhD, and Shawn Kwatra, MD, review how they have seen representation change in their own experiences.

The IL-17A inhibitor did not meet its phase 2b/3 clinical trial primary end point.

The FDA no longer restricts the donation of human cells, tissues, cellular or tissue-based products, human milk, ova, sperm, or organs for transplantation for patients who receive StrataGraft.

As deucravacitinib surpasses its 1-year milestone since approval, clinicians continue to monitor its real-world performance among patients.

ICYMI, this week we had articles about acne vulgaris management from an expert panel, a look back at summer dermatology conferences, long-term results of roflumilast cream 0.15% for AD, and more.

This week’s collection of the latest dermatologic studies covers the hair regrowth cycle in mice, considering large language models in dermatology, cutaneous leiomyosarcomas subtypes, and the efficacy of tralokinumab in older adults with atopic dermatitis.

Roflumilast maintained disease control when patients switched to twice-weekly dosing.

A panel of 9 dermatologists met and created 5 statements regarding the role of ceramide-containing skin care products in reducing skin barrier dysfunction related to acne treatments.

In this week’s Pointers With Portela, the 208SkinDoc takes an in-depth look at Merkel cell carcinoma after Jimmy Buffett passed away from a 4-year battle with the rare form of skin cancer.

Catch up on acne vulgaris treatment pearls from Dermatology Times’ most recent Frontline Forum series, featuring James Del Rosso, DO; Hilary Baldwin, MD; Neal Bhatia, MD; Christopher Bunick, MD, PhD; and Leon Kircik, MD.

ICYMI, this week we had articles about lowered infection risks with IL23i and IL-17i, a new trio combination cream for melasma treatment, tralokinumab's success among older patients with AD, and more.

Learn more about the in-depth topics covered in the August 2023 Frontline Forum acne vulgaris supplement of Dermatology Times.